Institute of Biomedical Research Corp. (OTC:MRES) Stock In Focus After Recent News
The Institute of Biomedical Research Corp. (OTC:MRES) is a pioneering company that is a major player in spaces like biotech and nutraceutical. It is known for its expertise in the development of plant-based psilocybin and CBDs. The company is also involved with advanced research into therapeutic mental health powered by artificial intelligence.
On February 23, the company was in the news cycle after it announced the launch of a path-breaking new division named M2Bio Kids. The division would be concerned with promoting physical and mental health in the formative years of a child. The division would focus on new-born children to those aged 5 years. The work of the division would be based on the cutting-edge intersection of pediatric health sciences and biotech. It was further noted that M2Bio Kids would help in transforming the development of a child in its early childhood through a thorough approach. The approach would consist of mental and physical exercises, food, nutrition, and critical thinking through artificial intelligence-powered applications.
In the news release, the company noted that the initial years of the life of a child are the foundations of a healthy life in the long term. It also included superior cognitive abilities as well as well-being. The company noted that it recognized the possibilities of making an immense impact during this crucial period in a person’s life.
The new division would deploy its advanced scientific research for the purpose of developing high-tech solutions as well as strategies that could help in better health, growth, and developmental outcomes. It was also noted that proper nutrition remained the most important aspect of the healthy development of a child. The research from the Institute of Biomedical Research Corp. had been focused on the identification of the best dietary patterns and intakes of micronutrients.
